
  
    
      
        Introduction
        <ENAMEX TYPE="ORGANIZATION">Autoreactive T</ENAMEX> cells are primarily eliminated in the
        thymus by negative selection (central tolerance). Some of
        the autoreactive T cells, however, may escape from negative
        selection and are released into the periphery. These
        <ENAMEX TYPE="ORGANIZATION">self-reactive T</ENAMEX> cells are exquisitely regulated, and their
        <ENAMEX TYPE="ORGANIZATION">activation</ENAMEX> can result in autoimmune <ENAMEX TYPE="DISEASE">diseases</ENAMEX>. There is
        accumulating evidence that, in addition to
        activation-induced cell death or anergy, <ENAMEX TYPE="GPE">T-cell</ENAMEX>-mediated
        dominant control of self-reactive T cells represents one
        mechanism for maintaining immunological tolerance [ <NUMEX TYPE="CARDINAL">1 2 3</NUMEX> ]
        . Studies conducted in a number of experimental models have
        demonstrated the existence of regulatory T-cell subsets
        that prevent activation of autoreactive T cells. Recently,
        a subset of <NUMEX TYPE="CARDINAL">CD4</NUMEX> +T cells was identified that is present on
        <NUMEX TYPE="CARDINAL">5</NUMEX>-<NUMEX TYPE="PERCENT">10%</NUMEX> of <NUMEX TYPE="CARDINAL">CD4</NUMEX> +T cells in normal na√Øve <ENAMEX TYPE="ANIMAL">mice</ENAMEX> and expresses
        CD25 (the Œ±-<ENAMEX TYPE="ORG_DESC">chain</ENAMEX> of <ENAMEX TYPE="SUBSTANCE">IL-2 receptor</ENAMEX>) [ <NUMEX TYPE="CARDINAL">4 5</NUMEX> ] . Functional
        analysis of murine <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +T cells showed that those
        cells, which <ENAMEX TYPE="PER_DESC">constitutively</ENAMEX> express cytotoxic <ENAMEX TYPE="PRODUCT">T-</ENAMEX>lymphocyte
        <ENAMEX TYPE="PERSON">antigen</ENAMEX> (CTLA)-<NUMEX TYPE="CARDINAL">4</NUMEX> [ <NUMEX TYPE="CARDINAL">6 7 8</NUMEX> ] , fail to proliferate or secret
        <ENAMEX TYPE="ORGANIZATION">cytokines</ENAMEX> in response to polyclonal or <ENAMEX TYPE="SUBSTANCE">antigen</ENAMEX>-specific
        <ENAMEX TYPE="PERSON">stimulation</ENAMEX>, but inhibit the activation of conventional
        <ENAMEX TYPE="ORGANIZATION">responsive T</ENAMEX> cells [ <NUMEX TYPE="CARDINAL">1 2 3 8 9</NUMEX> ] . The suppressive activity
        of the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +T cells depends on signaling via the
        negative <ENAMEX TYPE="PER_DESC">regulator</ENAMEX> of <ENAMEX TYPE="ORGANIZATION">T-cell</ENAMEX> activation <ENAMEX TYPE="SUBSTANCE">CTLA-4</ENAMEX> [ <ENAMEX TYPE="LAW">7</ENAMEX> ] and
        requires a cell-cell interaction that possibly involves
        cell surface bound transforming growth <ENAMEX TYPE="SUBSTANCE">factor</ENAMEX> (TGF)-Œ≤ 
        <NUMEX TYPE="CARDINAL">1</NUMEX> [ <ENAMEX TYPE="LAW">1 10</ENAMEX> ] . It has been shown that
        <ENAMEX TYPE="CONTACT_INFO">B7/CD28</ENAMEX> costimulation is essential for the development and
        homeostasis of the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells [ <ENAMEX TYPE="LAW">6</ENAMEX> ] ,
        which play critical roles not only in preventing
        autoimmunity but also in controlling <ENAMEX TYPE="DISEASE">tumor immunity</ENAMEX> and
        transplantation tolerance [ <ENAMEX TYPE="LAW">2 11</ENAMEX> ] .
        Proteoglycan-induced <ENAMEX TYPE="DISEASE">arthritis</ENAMEX> (PGIA) is a novel
        <ENAMEX TYPE="PRODUCT">autoimmune</ENAMEX> <ENAMEX TYPE="PRODUCT_DESC">murine model</ENAMEX> that is induced by systemic
        immunization of <ENAMEX TYPE="PRODUCT">BALB/c</ENAMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX> with <ENAMEX TYPE="SUBSTANCE">cartilage proteoglycans</ENAMEX> [
        <NUMEX TYPE="CARDINAL">12 13</NUMEX> ] . The development of <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX> is based on the
        <ENAMEX TYPE="ORGANIZATION">cross</ENAMEX>-reactive immune response between immunizing human and
        <ENAMEX TYPE="ANIMAL">mouse</ENAMEX> (self) <ENAMEX TYPE="SUBSTANCE">cartilage proteoglycans</ENAMEX> in genetically
        <ENAMEX TYPE="PRODUCT">susceptible BALB/c</ENAMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX> [ <NUMEX TYPE="CARDINAL">12 13</NUMEX> ] . Several lines of
        evidence indicate T-cell involvement in the pathogenesis of
        <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX>. First, <NUMEX TYPE="CARDINAL">CD4</NUMEX> +T cells selectively proliferate in
        response to proteoglycan antigens [ <TIMEX TYPE="DATE">14</TIMEX> ] . <NUMEX TYPE="ORDINAL">Second</NUMEX>,
        prevention of <ENAMEX TYPE="DISEASE">arthritis</ENAMEX> can be achieved by 
        in vivo treatment with anti-CD4
        monoclonal <ENAMEX TYPE="SUBSTANCE">antibodies</ENAMEX> [ <TIMEX TYPE="DATE">15</TIMEX> ] . <NUMEX TYPE="ORDINAL">Third</NUMEX>, <ENAMEX TYPE="DISEASE">arthritis</ENAMEX> can be
        transferred to na√Øve <ENAMEX TYPE="PRODUCT">BALB/c</ENAMEX> or severe combined
        <ENAMEX TYPE="ORGANIZATION">immunodeficient</ENAMEX> (SCID) <ENAMEX TYPE="ANIMAL">mice</ENAMEX> using T and B cells from
        <ENAMEX TYPE="ANIMAL">arthritic animals</ENAMEX> [ <NUMEX TYPE="CARDINAL">16 17 18</NUMEX> ] . <NUMEX TYPE="ORDINAL">Fourth</NUMEX>, a
        proteoglycan-specific <ENAMEX TYPE="NATIONALITY">T-cell</ENAMEX> hybridoma (<ENAMEX TYPE="NATIONALITY">T-helper</ENAMEX>-<NUMEX TYPE="CARDINAL">1</NUMEX> type)
        can induce <ENAMEX TYPE="DISEASE">arthritis</ENAMEX> in <ENAMEX TYPE="ORGANIZATION">BALB</ENAMEX><ENAMEX TYPE="PRODUCT">/c</ENAMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX> [ <TIMEX TYPE="DATE">19</TIMEX> ] . Finally, CD4
        <ENAMEX TYPE="ORGANIZATION">+T</ENAMEX> cells from <ENAMEX TYPE="ANIMAL">arthritic animals</ENAMEX> are resistant to
        activation-induced cell death [ <TIMEX TYPE="DATE">20</TIMEX> ] . These data suggest a
        breakdown of peripheral tolerance and accumulation of
        <ENAMEX TYPE="ORGANIZATION">autoreactive T</ENAMEX> cells in the periphery.
        In order to determine whether <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T
        cells play a role in the development of <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX>, we monitored
        the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +-expressing regulatory T cells in <ENAMEX TYPE="ANIMAL">mice</ENAMEX> with
        <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX> during an entire immunization period. We also
        transferred purified <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +T cells from <ENAMEX TYPE="DISEASE">na√Øve BALB</ENAMEX>/c
        <ENAMEX TYPE="ANIMAL">mice</ENAMEX> together with spleen cells from <ENAMEX TYPE="ANIMAL">arthritic animals</ENAMEX>, or
        alternatively transferred <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +-depleted spleen cells
        from arthritic <ENAMEX TYPE="ANIMAL">animals</ENAMEX> into <ENAMEX TYPE="ORGANIZATION">SCID</ENAMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX>, and then monitored
        <ENAMEX TYPE="DISEASE">disease</ENAMEX> development in SCID <ENAMEX TYPE="ANIMAL">mice</ENAMEX>. In addition, we examined
        disease incidence in <NUMEX TYPE="CARDINAL">CD28</NUMEX>-deficient <ENAMEX TYPE="ANIMAL">mice</ENAMEX>, which have
        <ENAMEX TYPE="DISEASE">deficiency</ENAMEX> in <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +T cells. Our data suggest that the
        CD4 +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells might not be essential for
        controlling the development of <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX>.
      
      
        Materials and methods
        
          <ENAMEX TYPE="PERSON">Antigen</ENAMEX>, <ENAMEX TYPE="ANIMAL">mice</ENAMEX> and immunization
          High-density <ENAMEX TYPE="SUBSTANCE">cartilage proteoglycan</ENAMEX> (aggrecan) was
          purified from human <ENAMEX TYPE="SUBSTANCE">cartilage</ENAMEX>, by <ENAMEX TYPE="ORGANIZATION">CsCl</ENAMEX> gradient
          centrifugation, and depleted of glycosaminoglycan side
          chains as described previously [ <TIMEX TYPE="DATE">21</TIMEX> ] . <ENAMEX TYPE="CONTACT_INFO">Female BALB/c</ENAMEX>
          <ENAMEX TYPE="ANIMAL">mice</ENAMEX> (<ENAMEX TYPE="ORGANIZATION">National Cancer Institute</ENAMEX>, <ENAMEX TYPE="PERSON">Friedrich</ENAMEX>, <ENAMEX TYPE="PRODUCT">MD</ENAMEX>, <ENAMEX TYPE="ORGANIZATION">USA</ENAMEX>, or
          The <ENAMEX TYPE="ORGANIZATION">Jackson Laboratory</ENAMEX>, <ENAMEX TYPE="GPE">Bar Harbor</ENAMEX>, ME, <ENAMEX TYPE="ORGANIZATION">USA</ENAMEX>) and
          CD28-deficient <ENAMEX TYPE="ANIMAL">mice</ENAMEX> (The <ENAMEX TYPE="ORGANIZATION">Jackson Laboratory</ENAMEX>) were
          immunized intraperitoneally with <ENAMEX TYPE="SUBSTANCE">cartilage</ENAMEX> proteoglycan
          (<NUMEX TYPE="CARDINAL">100</NUMEX> Œºg <ENAMEX TYPE="SUBSTANCE">protein</ENAMEX>) in complete <ENAMEX TYPE="PERSON">Freund</ENAMEX>'s adjuvant on <TIMEX TYPE="DATE">day 0</TIMEX>,
          and boosted with proteoglycan in incomplete <ENAMEX TYPE="PERSON">Freund</ENAMEX>'s
          adjuvant on <TIMEX TYPE="DATE">days 21 and 42</TIMEX>. Female <ENAMEX TYPE="ANIMAL">SCID mice</ENAMEX> on a <ENAMEX TYPE="DISEASE">BALB</ENAMEX>/c
          background (<ENAMEX TYPE="ORGANIZATION">NCI/NCrC</ENAMEX>.B-<NUMEX TYPE="CARDINAL">17</NUMEX>-scid/scid), aged <TIMEX TYPE="DATE">8-12 weeks</TIMEX> or
          young retired <ENAMEX TYPE="PER_DESC">breeders</ENAMEX>, were purchased from the National
          <ENAMEX TYPE="ORGANIZATION">Cancer Institute</ENAMEX> and maintained under germ-free
          conditions.
        
        
          Assessment of <ENAMEX TYPE="DISEASE">arthritis</ENAMEX>
          A standard scoring system, based on swelling and
          redness of each paw, was used for the assessment of the
          severity of <ENAMEX TYPE="DISEASE">disease</ENAMEX>. The first clinical symptom of
          swelling was recorded as the time of onset of <ENAMEX TYPE="DISEASE">arthritis</ENAMEX>.
          Joint swelling was scored (ranging from <TIMEX TYPE="DATE">0 to 4</TIMEX> in each
          <ENAMEX TYPE="ORGANIZATION">paw</ENAMEX>) and expressed as acute cumulative <ENAMEX TYPE="DISEASE">arthritis</ENAMEX> score,
          resulting in a possible maximum severity score of <NUMEX TYPE="CARDINAL">16</NUMEX>.
          Typically, in the primary form of <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX>, <ENAMEX TYPE="PRODUCT">BALB/c</ENAMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX>
          developed swelling and redness in one or more limbs <NUMEX TYPE="CARDINAL">7-14</NUMEX>
          <TIMEX TYPE="DATE">days</TIMEX> after the <NUMEX TYPE="ORDINAL">third</NUMEX> injection with proteoglycan and
          <ENAMEX TYPE="ORGANIZATION">adjuvant</ENAMEX>. In the transfer system, <ENAMEX TYPE="PER_DESC">recipient</ENAMEX> SCID <ENAMEX TYPE="ANIMAL">mice</ENAMEX>
          developed a more uniform disease <TIMEX TYPE="DATE">from day 10</TIMEX> after
          transfer, with involvement of nearly all peripheral
          <ENAMEX TYPE="PERSON">joints</ENAMEX>.
        
        
          Flow cytometry analysis
          The <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +-expressing T cells were identified by
          staining spleen cells with fluorescein isothiocyanate
          (<ENAMEX TYPE="ORGANIZATION">FITC</ENAMEX>)-labeled anti-<NUMEX TYPE="CARDINAL">CD4</NUMEX> and biotin-labeled anti-CD25
          followed by <ENAMEX TYPE="GPE">CyChrome</ENAMEX>-labeled streptavidin (<ENAMEX TYPE="ORGANIZATION">BD PharMingen</ENAMEX>,
          <ENAMEX TYPE="GPE">San Diego</ENAMEX>, CA, <ENAMEX TYPE="ORGANIZATION">USA</ENAMEX>), and analyzed on a flow cytometer
          (<ENAMEX TYPE="ORGANIZATION">Beckton Dickinson</ENAMEX>, <ENAMEX TYPE="GPE">San Jose</ENAMEX>, CA, <ENAMEX TYPE="ORGANIZATION">USA</ENAMEX>). For analysis of
          <ENAMEX TYPE="ORGANIZATION">intracellular</ENAMEX> <ENAMEX TYPE="PRODUCT">CTLA-4</ENAMEX>, spleen cells were first stained
          with the above fluorescence-labeled antibodies, fixed and
          rendered permeable, and stained with <ENAMEX TYPE="NATIONALITY">R</ENAMEX>-phycoerythrin
          (<ENAMEX TYPE="ORGANIZATION">PE</ENAMEX>)-labeled anti-<ENAMEX TYPE="PRODUCT">CTLA-4</ENAMEX> using a Cytofix/Cytoperm kit (BD
          <ENAMEX TYPE="ORGANIZATION">PharMingen</ENAMEX>).
        
        
          Purification of <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +and <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> -T cells
          and cell transfer in SCID <ENAMEX TYPE="ANIMAL">mice</ENAMEX>
          The <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +T cells were purified using a protocol
          described previously [ <ENAMEX TYPE="LAW">6</ENAMEX> ] . Briefly, <NUMEX TYPE="CARDINAL">CD4</NUMEX> +T cells were
          isolated from spleens of <NUMEX TYPE="CARDINAL">10- to 12</NUMEX><TIMEX TYPE="DATE">-week-old</TIMEX>, na√Øve,
          <ENAMEX TYPE="ORGANIZATION">BALB</ENAMEX><ENAMEX TYPE="PRODUCT">/c</ENAMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX> by negative selection using CD4-enrichment
          columns (<ENAMEX TYPE="ORGANIZATION">R&D System</ENAMEX>, <ENAMEX TYPE="GPE">Minneapolis</ENAMEX>, <ENAMEX TYPE="ORGANIZATION">MN</ENAMEX>, <ENAMEX TYPE="ORGANIZATION">USA</ENAMEX>). Purified
          CD4 +T cells were incubated with PE-labeled anti-<NUMEX TYPE="CARDINAL">CD25</NUMEX>,
          and the stained cells were incubated with anti-PE
          <ENAMEX TYPE="ORGANIZATION">microbeads</ENAMEX> (<ENAMEX TYPE="ORGANIZATION">Miltenyi Biotech Inc.</ENAMEX>, <ENAMEX TYPE="GPE">Auburn</ENAMEX>, CA, <ENAMEX TYPE="ORGANIZATION">USA</ENAMEX>). The
          CD25 +cells were selected on an <ENAMEX TYPE="WORK_OF_ART">LS +</ENAMEX>column (Miltenyi
          <ENAMEX TYPE="ORGANIZATION">Biotech Inc.</ENAMEX>). The purity of the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +T cells was
          <NUMEX TYPE="PERCENT">approximately 90%</NUMEX>. The <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> -T cells, which did not
          bind to magnetic beads, were collected from the flow
          through the washing steps (purity ><NUMEX TYPE="PERCENT">98%</NUMEX>). A total of <NUMEX TYPE="CARDINAL">5</NUMEX>
          √ó <NUMEX TYPE="CARDINAL">10 5CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +or <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> -T cells were injected
          intraperitoneally, along with <NUMEX TYPE="CARDINAL">1</NUMEX> √ó <NUMEX TYPE="CARDINAL">10 7spleen</NUMEX> cells from
          <ENAMEX TYPE="ANIMAL">arthritic animals</ENAMEX> that were depleted of <NUMEX TYPE="CARDINAL">CD25</NUMEX> +cells and
          <NUMEX TYPE="CARDINAL">100</NUMEX> Œºg proteoglycan, into <ENAMEX TYPE="ORGANIZATION">SCID</ENAMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX>.
        
        
          Depletion of <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +T cells and cell
          transfer
          Spleen cells from <ENAMEX TYPE="ANIMAL">arthritic animals</ENAMEX> were depleted of
          CD25 +cells using negative selection as described above
          (<NUMEX TYPE="QUANTITY">0.5 Œºg</NUMEX> PE-labeled anti-<NUMEX TYPE="CARDINAL">CD25</NUMEX> per <NUMEX TYPE="QUANTITY">1 √ó 10 6cells</NUMEX>). The
          depletion of <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +cells was detected by flow
          <ENAMEX TYPE="ORGANIZATION">cytometry</ENAMEX>. Typically, less than <NUMEX TYPE="PERCENT">0.3%</NUMEX> of the depleted
          cells expressed CD25. a total of <NUMEX TYPE="CARDINAL">1</NUMEX> √ó <NUMEX TYPE="CARDINAL">10 7CD25</NUMEX> +and CD25
          -spleen cells, together with <NUMEX TYPE="QUANTITY">100 Œºg</NUMEX> proteoglycan, were
          injected intraperitoneally into <ENAMEX TYPE="ORGANIZATION">SCID</ENAMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX>.
        
        
          In vitro suppression assay
          CD4 +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +T cells (<ENAMEX TYPE="CONTACT_INFO">1 √ó 10 4</ENAMEX>) isolated from na√Øve
          <ENAMEX TYPE="ORGANIZATION">BALB</ENAMEX><ENAMEX TYPE="PRODUCT">/c</ENAMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX> were mixed with <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> -T <ENAMEX TYPE="SUBSTANCE">cells</ENAMEX> (<ENAMEX TYPE="CONTACT_INFO">5 √ó 10 4</ENAMEX>)
          from arthritic <ENAMEX TYPE="ANIMAL">mice</ENAMEX> in the presence of irradiated
          syngenic splenocytes as <ENAMEX TYPE="SUBSTANCE">antigen-presenting cells</ENAMEX> (<NUMEX TYPE="MONEY">7.5</NUMEX> √ó
          <NUMEX TYPE="CARDINAL">10 4</NUMEX>) with <NUMEX TYPE="QUANTITY">1 Œ</NUMEX>ºg/ml soluble anti-<NUMEX TYPE="CARDINAL">CD3</NUMEX> for <TIMEX TYPE="DATE">3 days</TIMEX> or <NUMEX TYPE="CARDINAL">50</NUMEX>
          <ENAMEX TYPE="CONTACT_INFO">Œºg/ml</ENAMEX> proteoglycan for <TIMEX TYPE="DATE">5 days</TIMEX>, and <ENAMEX TYPE="ORGANIZATION">T-cell</ENAMEX> proliferation
          was determined by [ <TIMEX TYPE="DATE">3H</TIMEX>]thymidine incorporation.
        
        
          Measurements of <ENAMEX TYPE="SUBSTANCE">antigen</ENAMEX>-specific <ENAMEX TYPE="ORGANIZATION">T-cell</ENAMEX> responses,
          <ENAMEX TYPE="PERSON">antibodies</ENAMEX>, and cytokine production
          <ENAMEX TYPE="PERSON">Antigen</ENAMEX>-specific <ENAMEX TYPE="ORGANIZATION">T-cell</ENAMEX> responses were measured in
          quadriplicate samples of spleen cells (<ENAMEX TYPE="CONTACT_INFO">3 √ó 10</ENAMEX>
          5cells/well) cultured in the presence of <NUMEX TYPE="QUANTITY">50 Œ</NUMEX>ºg
          proteoglycan <ENAMEX TYPE="SUBSTANCE">protein</ENAMEX>/ml. T-cell proliferation was
          assessed on <TIMEX TYPE="DATE">day 5</TIMEX> by [ <TIMEX TYPE="DATE">3H</TIMEX>]thymidine incorporation [ <NUMEX TYPE="CARDINAL">14 22</NUMEX>
          ] . <ENAMEX TYPE="PERSON">Antigen</ENAMEX> (proteoglycan)-specific <ENAMEX TYPE="SUBSTANCE">interferon-Œ≥</ENAMEX>, <ENAMEX TYPE="PRODUCT">IL-10</ENAMEX>,
          and <ENAMEX TYPE="PRODUCT">IL-4</ENAMEX> production by <ENAMEX TYPE="ORGANIZATION">T</ENAMEX> cells was determined in media
          collected on <TIMEX TYPE="DATE">day 4</TIMEX> using capture enzyme-linked
          immunosorbent assays (ELISAs) from <ENAMEX TYPE="ORGANIZATION">BioSource</ENAMEX>
          <ENAMEX TYPE="ORGANIZATION">International, Inc.</ENAMEX> (<ENAMEX TYPE="ORGANIZATION">Camarillo</ENAMEX>, CA, <ENAMEX TYPE="ORGANIZATION">USA</ENAMEX>). For induction
          of <ENAMEX TYPE="ORGANIZATION">TGF</ENAMEX>-Œ≤ 
          <NUMEX TYPE="CARDINAL">1</NUMEX> , spleen cells were cultured in
          serum-free medium <ENAMEX TYPE="LAW">X-Vivo-20</ENAMEX> (<ENAMEX TYPE="ORGANIZATION">BioWhittaker, Inc.</ENAMEX>,
          Walkersville, <ENAMEX TYPE="PRODUCT">MD</ENAMEX>, <ENAMEX TYPE="ORGANIZATION">USA</ENAMEX>) in the presence of proteoglycan.
          Total <ENAMEX TYPE="ORGANIZATION">TGF</ENAMEX>-Œ≤ 
          <NUMEX TYPE="CARDINAL">1</NUMEX> was measured after acidification to
          activate latent TGF-Œ≤, followed by neutralization using
          an ELISA kit from <ENAMEX TYPE="PERSON">Promega</ENAMEX> (<ENAMEX TYPE="GPE">Madison</ENAMEX>, <ENAMEX TYPE="ORGANIZATION">WI</ENAMEX>, <ENAMEX TYPE="ORGANIZATION">USA</ENAMEX>).
          Maxisorp immunoplates (<ENAMEX TYPE="ORGANIZATION">Nunc</ENAMEX>, <ENAMEX TYPE="GPE">Rochester</ENAMEX>, <ENAMEX TYPE="ORGANIZATION">NY</ENAMEX>, <ENAMEX TYPE="ORGANIZATION">USA</ENAMEX>) were
          coated with human or mouse <ENAMEX TYPE="SUBSTANCE">cartilage proteoglycans</ENAMEX> (<NUMEX TYPE="CARDINAL">0.1</NUMEX>
          Œºg <ENAMEX TYPE="SUBSTANCE">protein</ENAMEX><NUMEX TYPE="QUANTITY">/100 Œºl</NUMEX> per well) for <ENAMEX TYPE="ORGANIZATION">ELISA</ENAMEX>, and free binding
          capacity of the <ENAMEX TYPE="FAC_DESC">wells</ENAMEX> was blocked by <NUMEX TYPE="PERCENT">1%</NUMEX> fat-free <ENAMEX TYPE="SUBSTANCE">milk</ENAMEX> in
          <ENAMEX TYPE="ORGANIZATION">phosphate</ENAMEX>-buffered saline [ <NUMEX TYPE="CARDINAL">23 24 25</NUMEX> ] . Sera were
          <ENAMEX TYPE="ORGANIZATION">applied</ENAMEX> at increasing dilutions and isotypes of
          proteoglycan-specific <ENAMEX TYPE="SUBSTANCE">antibodies</ENAMEX> were determined using
          peroxidase-conjugated <ENAMEX TYPE="ANIMAL">rat antimouse</ENAMEX> IgG 
          <NUMEX TYPE="CARDINAL">1</NUMEX> or IgG 
          2a secondary <ENAMEX TYPE="SUBSTANCE">antibodies</ENAMEX> (<ENAMEX TYPE="ORGANIZATION">Zymed</ENAMEX>, <ENAMEX TYPE="GPE">South</ENAMEX>
          <ENAMEX TYPE="GPE">San Francisco</ENAMEX>, CA, <ENAMEX TYPE="ORGANIZATION">USA</ENAMEX>) as previously described [ <NUMEX TYPE="CARDINAL">24 26</NUMEX> ]
          . Serum <ENAMEX TYPE="SUBSTANCE">antibody</ENAMEX> levels were calculated according to
          <ENAMEX TYPE="PERSON">mouse IgG</ENAMEX> 
          <NUMEX TYPE="CARDINAL">1</NUMEX> and IgG 
          2a standards. <ENAMEX TYPE="PERSON">Mouse IgG</ENAMEX> 
          <NUMEX TYPE="CARDINAL">1</NUMEX> and IgG 
          2a standards were purified by
          sepharose-coupled protein <ENAMEX TYPE="ORGANIZATION">G</ENAMEX> from irrelevant
          (non-<NUMEX TYPE="CARDINAL">proteoglycan</NUMEX>-specific) monoclonal
          <ENAMEX TYPE="SUBSTANCE">antibody-containing ascites fluids</ENAMEX> and coated directly
          onto the <ENAMEX TYPE="ORG_DESC">microplate</ENAMEX>'s surface.
        
        
          Statistical analysis
          Statistical analysis was performed using <ENAMEX TYPE="SUBSTANCE">SPSS</ENAMEX> v7.5
          (<ENAMEX TYPE="ORGANIZATION">SPSS</ENAMEX>, <ENAMEX TYPE="GPE">Chicago</ENAMEX>, <ENAMEX TYPE="ORGANIZATION">IL</ENAMEX>, <ENAMEX TYPE="ORGANIZATION">USA</ENAMEX>). The <ENAMEX TYPE="PERSON">Mann-Whitney</ENAMEX> and Wilcoxon
          tests were used for intergroup comparisons. 
          <ENAMEX TYPE="PRODUCT">P < 0.05</ENAMEX> was considered
          statistically significant.
        
      
      
        Results
        
          Lack of correlation between development of
          <ENAMEX TYPE="ORGANIZATION">arthritis</ENAMEX> and expression of <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells
          in PGIA
          To elucidate the role of these regulatory T cells in
          autoimmune <ENAMEX TYPE="DISEASE">arthritis</ENAMEX>, we first followed up the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +CD25
          +-expressing regulatory T cells in <ENAMEX TYPE="ANIMAL">mice</ENAMEX> with <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX> during
          the entire course of immunization. To exclude the
          possibility that different CD4 +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +-expressing T cells
          may be a strain- and/or <ENAMEX TYPE="SUBSTANCE">antigen</ENAMEX>-dependent phenomenon, we
          <ENAMEX TYPE="ORGANIZATION">immunized</ENAMEX> <ENAMEX TYPE="PRODUCT">BALB/c</ENAMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX> (PGIA-susceptible strain) and
          C57BL<NUMEX TYPE="CARDINAL">/6</NUMEX> (<ENAMEX TYPE="DISEASE">arthritis</ENAMEX>-resistant strain) with human <ENAMEX TYPE="SUBSTANCE">cartilage</ENAMEX>
          <ENAMEX TYPE="ORGANIZATION">proteoglycan</ENAMEX> or ovalbumin. As shown in <ENAMEX TYPE="GPE">Fig</ENAMEX>. <ENAMEX TYPE="CONTACT_INFO">1, BALB/c</ENAMEX>
          <ENAMEX TYPE="ANIMAL">mice immunized</ENAMEX> with human <ENAMEX TYPE="SUBSTANCE">cartilage proteoglycan</ENAMEX> started
          to develop <ENAMEX TYPE="DISEASE">arthritis</ENAMEX> after the <NUMEX TYPE="ORDINAL">third</NUMEX> injection and the
          incidence of <ENAMEX TYPE="DISEASE">arthritis</ENAMEX> reached <NUMEX TYPE="PERCENT">100%</NUMEX> at <TIMEX TYPE="DATE">day 72</TIMEX> following
          the <NUMEX TYPE="ORDINAL">third</NUMEX> immunization, whereas <ENAMEX TYPE="ORGANIZATION">BALB</ENAMEX><ENAMEX TYPE="PRODUCT">/c</ENAMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX> immunized
          with ovalbumin or <NUMEX TYPE="CARDINAL">C57BL/6</NUMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX> immunized with
          proteoglycan were completely resistant to <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX>. The CD4
          +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +-expressing T cells detected <TIMEX TYPE="DATE">14 days</TIMEX> after each
          immunization from each experimental <ENAMEX TYPE="PER_DESC">group</ENAMEX> were similar
          during the entire course of immunization (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2a). This
          <ENAMEX TYPE="PERSON">observation</ENAMEX> suggests that the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T
          cells might not be involved in the development of <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX>.
          Although it has been shown that the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory
          <ENAMEX TYPE="ORGANIZATION">T</ENAMEX> cells can suppress the development of autoimmunity, a
          recent report [ <TIMEX TYPE="DATE">27</TIMEX> ] demonstrated that depletion of the
          CD4 +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +T cells is necessary but not sufficient for
          induction of autoimmune <ENAMEX TYPE="DISEASE">gastritis</ENAMEX>.
          It has been shown that the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T
          cells express <ENAMEX TYPE="PRODUCT">CTLA-4</ENAMEX> [ <NUMEX TYPE="CARDINAL">6 7 8</NUMEX> ] , which is a negative
          <ENAMEX TYPE="PER_DESC">regulator</ENAMEX> of <ENAMEX TYPE="ORGANIZATION">T-cell</ENAMEX> activation. The suppressive activity
          of the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells may in part be
          ascribed to signaling through CTLA-<NUMEX TYPE="CARDINAL">4</NUMEX>. <ENAMEX TYPE="SUBSTANCE">CTLA-4</ENAMEX> may
          transduce an activating signal to <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T
          cells [ <ENAMEX TYPE="LAW">2</ENAMEX> ] . Although we did not detect any significant
          decrease in numbers of the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells
          between proteoglycan-immunized <ENAMEX TYPE="PRODUCT">BALB/c</ENAMEX> and <NUMEX TYPE="CARDINAL">C57BL/6</NUMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX>,
          this might be due to reduced expression of <ENAMEX TYPE="SUBSTANCE">CTLA-4</ENAMEX> in the
          CD4 +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells from proteoglycan-immunized
          <ENAMEX TYPE="ORGANIZATION">BALB</ENAMEX><ENAMEX TYPE="PRODUCT">/c</ENAMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX>. To test this possibility, we then detected
          <ENAMEX TYPE="SUBSTANCE">CTLA-4</ENAMEX> expression on <TIMEX TYPE="DATE">the CD4</TIMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells
          using intracellular staining. There was no significant
          difference between levels of <ENAMEX TYPE="SUBSTANCE">CTLA-4</ENAMEX> expression in the CD4
          +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells from each group (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2b). This
          finding excludes the possibility that reduced expression
          of <ENAMEX TYPE="SUBSTANCE">CTLA-4</ENAMEX> in <TIMEX TYPE="DATE">the CD4</TIMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells from
          <ENAMEX TYPE="ORGANIZATION">BALB</ENAMEX><ENAMEX TYPE="PRODUCT">/c</ENAMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX> with <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX> may mediate the induction of the
          <ENAMEX TYPE="DISEASE">disease</ENAMEX>.
        
        
          CD4 +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells may not control
          autoimmune <ENAMEX TYPE="DISEASE">arthritis</ENAMEX>
          To further investigate whether the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +T cells
          play a role in <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX>, we performed adoptive transfer
          experiments using <ENAMEX TYPE="ORGANIZATION">SCID</ENAMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX> as <ENAMEX TYPE="PER_DESC">recipients</ENAMEX>. Purified CD4
          +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells (<NUMEX TYPE="CARDINAL">3-20 √ó 10 5</NUMEX>) from <ENAMEX TYPE="DISEASE">na√Øve BALB</ENAMEX>/c
          <ENAMEX TYPE="ANIMAL">mice</ENAMEX>, together with <NUMEX TYPE="CARDINAL">10 7spleen</NUMEX> cells from <ENAMEX TYPE="ANIMAL">arthritic mice</ENAMEX>
          that were depleted of <NUMEX TYPE="CARDINAL">CD25</NUMEX> +T cells and <NUMEX TYPE="QUANTITY">100 Œ</NUMEX>ºg
          proteoglycan, were injected <ENAMEX TYPE="ANIMAL">intraperitoneally</ENAMEX> into SCID
          <ENAMEX TYPE="ANIMAL">mice</ENAMEX> [ <TIMEX TYPE="DATE">18</TIMEX> ] , and the incidence and severity of disease
          were monitored. Note that we used different ratios of the
          CD4 +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells to the effector cells, and
          we did not observe any suppression of <ENAMEX TYPE="DISEASE">arthritis</ENAMEX>
          <ENAMEX TYPE="ORGANIZATION">development</ENAMEX>. As a control, the same number of <NUMEX TYPE="CARDINAL">CD4</NUMEX> +CD25
          -T cells, together with arthritogenic spleen cells that
          were depleted of <NUMEX TYPE="CARDINAL">CD25</NUMEX> +cells, and proteoglycan, were also
          <ENAMEX TYPE="ORGANIZATION">adoptively</ENAMEX> transferred into <ENAMEX TYPE="ORGANIZATION">SCID</ENAMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX>. The transfers of
          CD4 +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +T cells did not have any impact on incidence
          and severity of the disease in SCID <ENAMEX TYPE="ANIMAL">mice</ENAMEX> as compared with
          transfer of <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> -T <ENAMEX TYPE="SUBSTANCE">cells</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3a), suggesting that
          the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells did not protect SCID
          <ENAMEX TYPE="ANIMAL">mice</ENAMEX> from <ENAMEX TYPE="DISEASE">arthritis</ENAMEX>. To further verify these results, a
          depletion experiment was conducted. Spleen cells from
          <ENAMEX TYPE="ANIMAL">arthritic animals</ENAMEX>, either depleted of <NUMEX TYPE="CARDINAL">CD25</NUMEX> +cells or
          without depletion, were injected into <ENAMEX TYPE="ORGANIZATION">SCID</ENAMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX> together
          with proteoglycan. The incidence and severity of
          <ENAMEX TYPE="ORGANIZATION">arthritis</ENAMEX> in SCID <ENAMEX TYPE="ANIMAL">mice</ENAMEX> receiving <ENAMEX TYPE="SUBSTANCE">spleen cells</ENAMEX> containing
          CD25 +cells or spleen cells depleted of <NUMEX TYPE="CARDINAL">CD25</NUMEX> +cells were
          <ENAMEX TYPE="PERSON">identical</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3b). Proteoglycan-specific T-cell
          proliferation and production of <TIMEX TYPE="DATE">IL-4</TIMEX>, <ENAMEX TYPE="ORGANIZATION">interferon-Œ≥</ENAMEX>,
          <ENAMEX TYPE="PRODUCT">IL-10</ENAMEX>, <ENAMEX TYPE="ORGANIZATION">TGF</ENAMEX>-Œ≤ 
          <NUMEX TYPE="CARDINAL">1</NUMEX> and antiproteoglycan autoantibodies
          were comparable in both transfer <ENAMEX TYPE="ORG_DESC">groups</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3c). The
          inability of the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells to
          <ENAMEX TYPE="ORGANIZATION">suppress PGIA</ENAMEX> was not due to loss of their suppression
          activity, because 
          in vitro <TIMEX TYPE="DATE">the CD4</TIMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +T cells
          could effectively inhibit the proliferation of the CD4
          <ENAMEX TYPE="CONTACT_INFO">+CD25</ENAMEX> -T <ENAMEX TYPE="SUBSTANCE">cells</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3d, left <ENAMEX TYPE="ORG_DESC">panel</ENAMEX>). Interestingly,
          proteoglycan-induced proliferation of <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> -T cells
          could not be inhibited by the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +T cells (<ENAMEX TYPE="PERSON">Fig</ENAMEX>.
          3d, right <ENAMEX TYPE="ORG_DESC">panel</ENAMEX>), which is consistent with a recent
          report that the effective function of the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +CD25
          +regulatory T cells is T-cell <ENAMEX TYPE="SUBSTANCE">receptor</ENAMEX> (<ENAMEX TYPE="ORGANIZATION">TCR</ENAMEX>) specific [
          <NUMEX TYPE="CARDINAL">28</NUMEX> ] . Collectively, our data suggest that the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +CD25
          +regulatory T cells may not be involved in the
          development of <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX>.
        
        
          CD28-deficient <ENAMEX TYPE="ANIMAL">mice</ENAMEX> have severely reduced CD4 +CD25
          +regulatory T cells but are resistant to PGIA
          It has been shown that <ENAMEX TYPE="PRODUCT">CD28-B7</ENAMEX> <ENAMEX TYPE="PRODUCT_DESC">interaction</ENAMEX> is
          essential for the homeostasis of the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +CD25
          +regulatory T cells that control autoimmune <ENAMEX TYPE="DISEASE">diabetes</ENAMEX> [ <NUMEX TYPE="CARDINAL">6</NUMEX>
          ] . Consistent with that report, the expression of CD4
          +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells was found to be significantly
          reduced as compared with that in wild-type <ENAMEX TYPE="PRODUCT">BALB/c</ENAMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX>
          (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 4a). To investigate whether a deficiency in the CD4
          +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells may lead to an increase in the
          development of <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX>, we immunized wild-type and
          CD28-deficient <ENAMEX TYPE="PRODUCT">BALB/c</ENAMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX> with proteoglycan, and disease
          <ENAMEX TYPE="PERSON">incidence</ENAMEX> was monitored. In contrast to the report in
          autoimmune <ENAMEX TYPE="DISEASE">diabetes</ENAMEX> [ <ENAMEX TYPE="LAW">6</ENAMEX> ] , <ENAMEX TYPE="PRODUCT">CD28-deficient BALB/c</ENAMEX> <ENAMEX TYPE="ANIMAL">mice</ENAMEX>
          were highly resistant to induction of <ENAMEX TYPE="DISEASE">arthritis</ENAMEX>, albeit
          at a low percentage of the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells
          observed in these <ENAMEX TYPE="ANIMAL">mice</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 4b). Note that T cells from
          proteoglycan-immunized <NUMEX TYPE="CARDINAL">CD28</NUMEX>-deficient <ENAMEX TYPE="ANIMAL">mice proliferate</ENAMEX> in
          response to proteoglycan stimulation, albeit at a rate
          lower than that in wild-type T cells (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 4c),
          suggesting that <ENAMEX TYPE="PRODUCT">CD28-deficient T</ENAMEX> <ENAMEX TYPE="SUBSTANCE">cells</ENAMEX> can be effectively
          primed.
        
      
      
        Discussion
        A controlled balance between initiation and
        downregulation of immune responses (peripheral tolerance)
        is important for maintaining immune homeostasis, whereas
        dysfunctional immune regulation may lead to chronic
        inflammation or autoimmunity [ <TIMEX TYPE="DATE">29</TIMEX> ] . The <NUMEX TYPE="CARDINAL">CD4</NUMEX> +CD25
        +regulatory T cells have been shown to suppress
        <ENAMEX TYPE="ORGANIZATION">autoimmunity</ENAMEX> in several animal models [ <ENAMEX TYPE="LAW">2</ENAMEX> ] . To evaluate
        the role of the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells in <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX>,
        <NUMEX TYPE="CARDINAL">three</NUMEX> approaches were used. First, the numbers of the CD4
        +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +<ENAMEX TYPE="FAC_DESC">cells</ENAMEX> in spleens of susceptible versus resistant or
        ovalbumin <ENAMEX TYPE="ANIMAL">immunized mice</ENAMEX> were assessed by flow cytometry at
        <TIMEX TYPE="DATE">day 14</TIMEX> following immunization. No significant change in the
        numbers of the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +cells was observed among
        experimental <ENAMEX TYPE="PER_DESC">groups</ENAMEX> tested (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 2a). Moreover, the levels
        of expression of <ENAMEX TYPE="SUBSTANCE">CTLA-4</ENAMEX> in <TIMEX TYPE="DATE">the CD4</TIMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +cells was similar
        between <ENAMEX TYPE="ORG_DESC">groups</ENAMEX>. These data suggest that the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +CD25
        +cells may not be involved in the development of <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX>.
        Although the immune system had been perturbed by
        immunization, <NUMEX TYPE="CARDINAL">CD4</NUMEX> +T cells isolated <TIMEX TYPE="DATE">14 days</TIMEX> after
        immunization of each <ENAMEX TYPE="ORG_DESC">group</ENAMEX> did not show significant
        increase in <TIMEX TYPE="DATE">CD25</TIMEX> expression as compared with that in na√Øve
        <ENAMEX TYPE="ANIMAL">mice</ENAMEX>, suggesting that T cells activated by immunization had
        become resting memory T cells.
        To further evaluate the role of the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +<ENAMEX TYPE="FAC_DESC">cells</ENAMEX> in
        <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX>, an adoptive transfer system was employed. Different
        ratios of activated <ENAMEX TYPE="SUBSTANCE">effector cells</ENAMEX> (<NUMEX TYPE="CARDINAL">CD25</NUMEX>-depleted spleen
        cells) to <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +cells were tested in our cotransfer
        experiments. No suppression of development of <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX> in SCID
        <ENAMEX TYPE="ANIMAL">mice</ENAMEX> was observed. Although one could argue that the ratio
        of effector cells to regulatory cells is not sufficiently
        <ENAMEX TYPE="ORGANIZATION">great</ENAMEX> to inhibit <ENAMEX TYPE="DISEASE">disease</ENAMEX>, we tested a wide range of ratios
        of effector cells to regulatory cells (<ENAMEX TYPE="CONTACT_INFO">5-30 : 1</ENAMEX>) in our
        transfer system, and similar results were observed. We did
        not observe any inhibition at the ratios used in the
        present study. However, we cannot completely exclude the
        possibility that <TIMEX TYPE="TIME">1-4 : 1</TIMEX> ratios may be required for
        suppression of <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX>. In view of the published literature,
        this is unlikely because most studies of this type used
        ratios greater than <TIMEX TYPE="DATE">20</TIMEX> : <NUMEX TYPE="CARDINAL">1</NUMEX> [ <ENAMEX TYPE="LAW">6</ENAMEX> ] . This finding is further
        supported by the evidence that adoptive transfer of
        CD25-depleted splenocytes from <ENAMEX TYPE="ANIMAL">arthritic mice</ENAMEX> does not
        exacerbate disease in SCID <ENAMEX TYPE="ANIMAL">mice</ENAMEX>. The <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +T cells are
        functionally normal because the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +cells can
        significantly inhibit the proliferation of the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +CD25
        -cells induced by <ENAMEX TYPE="ORGANIZATION">TCR</ENAMEX> stimulation (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3d, left <ENAMEX TYPE="ORG_DESC">panel</ENAMEX>). No
        <ENAMEX TYPE="ORGANIZATION">alteration</ENAMEX> in <ENAMEX TYPE="PRODUCT">IL-10</ENAMEX> and <ENAMEX TYPE="PRODUCT">TGF-Œ≤</ENAMEX> production could be detected
        in <TIMEX TYPE="DATE">two</TIMEX> transfer <ENAMEX TYPE="ORG_DESC">groups</ENAMEX> (<ENAMEX TYPE="PERSON">Fig</ENAMEX>. 3c). Taken together, our data
        suggest that the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells may not
        regulate the development of <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX>.
        We found that <NUMEX TYPE="CARDINAL">CD28</NUMEX>-deficient <ENAMEX TYPE="ANIMAL">mice</ENAMEX>, which have a low
        frequency of <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +T cells, are resistant to <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX>.
        Although <NUMEX TYPE="CARDINAL">one</NUMEX> may argue that, in the absence of <TIMEX TYPE="DATE">CD28</TIMEX>, T-cell
        priming by proteoglycan immunization may be defective.
        However, <NUMEX TYPE="CARDINAL">CD28</NUMEX>-deficient T cells from proteoglycan-immunized
        <ENAMEX TYPE="ANIMAL">animals</ENAMEX> can proliferate in response to proteoglycan
        stimulation 
        in vitro , albeit at a rate lower
        than that in wild-type T cells, which is consistent with
        the report by <ENAMEX TYPE="GPE">Oliveira-dos-Santos</ENAMEX> 
        <ENAMEX TYPE="ORGANIZATION">et al</ENAMEX> . [ <TIMEX TYPE="DATE">30</TIMEX> ] . It has been
        demonstrated that, in the absence of <TIMEX TYPE="DATE">CD28</TIMEX> engagement, T
        cells require very high <ENAMEX TYPE="ORGANIZATION">TCR</ENAMEX> occupancy and prolonged
        <ENAMEX TYPE="PERSON">stimulation</ENAMEX>, whereas <NUMEX TYPE="ORDINAL">CD28</NUMEX> costimulation allows T cells to
        respond to lower degrees of <ENAMEX TYPE="ORGANIZATION">TCR</ENAMEX> occupancy [ <NUMEX TYPE="CARDINAL">30 31</NUMEX> ] . In
        support of this observation, <ENAMEX TYPE="PRODUCT">CD28 -/-</ENAMEX><ENAMEX TYPE="ANIMAL">mice</ENAMEX> can still mount
        <ENAMEX TYPE="ORGANIZATION">immune</ENAMEX> responses, which vary in magnitude and efficiency
        depending on the <ENAMEX TYPE="SUBSTANCE">antigen</ENAMEX> or infectious <ENAMEX TYPE="PER_DESC">agent</ENAMEX> [ <NUMEX TYPE="CARDINAL">30 32</NUMEX> ] .
        Our results and those reported by others [ <TIMEX TYPE="DATE">30</TIMEX> ] suggest
        that CD28 may regulate the threshold for <ENAMEX TYPE="ORGANIZATION">T-cell</ENAMEX> activation.
        In support of this notion, immunization of <NUMEX TYPE="CARDINAL">CD28</NUMEX>-deficient
        <ENAMEX TYPE="ANIMAL">mice</ENAMEX> with high concentrations of myelin basic protein
        induces experimental autoimmune <ENAMEX TYPE="DISEASE">encephalomyelitis</ENAMEX> at
        similar prevalence and severity as in wild-type <ENAMEX TYPE="ANIMAL">mice</ENAMEX> [ <TIMEX TYPE="DATE">30</TIMEX> ]
        . Our data suggest that the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells
        might be important for controlling spontaneous models of
        autoimmunity but not for induced <ENAMEX TYPE="PER_DESC">models</ENAMEX> of autoimmunity. In
        <ENAMEX TYPE="ORGANIZATION">induced</ENAMEX> models of autoimmunity, the <ENAMEX TYPE="PRODUCT">CD28-B7</ENAMEX> <ENAMEX TYPE="PRODUCT_DESC">interaction</ENAMEX> has
        been shown to regulate disease susceptibility by rendering
        <ENAMEX TYPE="ORGANIZATION">autoreactive T</ENAMEX> cells anergic, or alternatively by
        upregulating the threshold for autoreactive T-cell
        <ENAMEX TYPE="ORGANIZATION">activation</ENAMEX> [ <TIMEX TYPE="DATE">30</TIMEX> ] . Furthermore, we previously showed that
        <ENAMEX TYPE="PERSON">impaired Fas</ENAMEX>-mediated activation-induced cell death (AICD)
        of autoreactive T-helper-<NUMEX TYPE="CARDINAL">1</NUMEX> cells may be responsible for the
        development of <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX> [ <TIMEX TYPE="DATE">20</TIMEX> ] . Therefore, <ENAMEX TYPE="ORGANIZATION">AICD</ENAMEX> and/or T-cell
        anergy, but not the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells, may be
        responsible for deletion or inactivation of autoreactive T
        cells in autoimmune <ENAMEX TYPE="DISEASE">arthritis</ENAMEX>.
      
      
        Conclusion
        Our results showed that the percentage of the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +CD25
        +regulatory T cells does not change during the development
        of <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX>. The <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells do not protect
        SCID <ENAMEX TYPE="ANIMAL">mice</ENAMEX> from <ENAMEX TYPE="DISEASE">arthritis</ENAMEX> when they are cotransferred with
        spleen cells from <ENAMEX TYPE="ANIMAL">arthritic mice</ENAMEX> and proteoglycan into SCID
        <ENAMEX TYPE="ANIMAL">mice</ENAMEX>. Transfer of spleen cells from <ENAMEX TYPE="ANIMAL">arthritic mice</ENAMEX>,
        depleted of the <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells, into SCID
        <ENAMEX TYPE="ANIMAL">mice</ENAMEX> does not accelerate the disease. Furthermore,
        CD28-deficient <ENAMEX TYPE="ANIMAL">mice</ENAMEX>, which are deficient for <NUMEX TYPE="CARDINAL">CD4</NUMEX> +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +T
        cells, are resistant to <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX>. Our data suggest that the CD4
        +<NUMEX TYPE="CARDINAL">CD25</NUMEX> +regulatory T cells may not be essential for
        controlling experimentally induced autoimmune
        <ENAMEX TYPE="DISEASE">arthritis</ENAMEX>.
      
      
        Competing interests
        None declared.
      
      
        Abbreviations
        <ENAMEX TYPE="ORGANIZATION">AICD</ENAMEX> = <NUMEX TYPE="CARDINAL">activation</NUMEX>-induced cell death; <ENAMEX TYPE="ORGANIZATION">CTLA</ENAMEX> = cytotoxic
        <ENAMEX TYPE="ORGANIZATION">T</ENAMEX>-lymphocyte <ENAMEX TYPE="SUBSTANCE">antigen</ENAMEX>; <ENAMEX TYPE="PERSON">ELISA</ENAMEX> = <NUMEX TYPE="CARDINAL">enzyme</NUMEX>-linked immunosorbent
        <ENAMEX TYPE="ORGANIZATION">assay; FITC</ENAMEX> = fluorescein isothiocyanate; <ENAMEX TYPE="ORGANIZATION">IL</ENAMEX> = <ENAMEX TYPE="PER_DESC">interleukin</ENAMEX>;
        <ENAMEX TYPE="ORGANIZATION">PE</ENAMEX> = <ENAMEX TYPE="NATIONALITY">R</ENAMEX>-phycoerythrin; PG = <ENAMEX TYPE="PER_DESC">proteoglycan</ENAMEX>; <ENAMEX TYPE="ORGANIZATION">PGIA</ENAMEX>,
        proteoglycan-induced <ENAMEX TYPE="DISEASE">arthritis</ENAMEX>; <ENAMEX TYPE="ORGANIZATION">SCID</ENAMEX> = severe combined
        <ENAMEX TYPE="ORGANIZATION">immunodeficient; TCR</ENAMEX> = <ENAMEX TYPE="SUBSTANCE">T-cell</ENAMEX> receptor; <ENAMEX TYPE="ORGANIZATION">TGF</ENAMEX> = transforming
        growth factor; <ENAMEX TYPE="ORGANIZATION">WT</ENAMEX> = wild-type.
      
    
  
